drug
EXEMESTANE
Marketedupdated 6mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(8)
approval · 8
Apr 1, 2011
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 3, 2011
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jul 6, 2015
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jul 6, 2015
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 13, 2020
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 13, 2020
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jun 15, 2022
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Oct 7, 2025
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Trials studying EXEMESTANE
- phase2A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
- phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- phase3A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- phase1A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- phase3A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- phase3A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- phase3Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that